Kevin Xu

Kevin Xu is the CEO of MEBO International, a California- and Beijing-based intellectual property management company specializing in applied health systems. He also leads Skingenix, which specializes in skin organ regeneration and the research and development of botanical drug products. Kevin is co-founder of the Human Heritage Project.

Posts by Kevin Xu

presented by
MedCity Influencers

3 ways to hire — and keep — your biotech talent

The biotech field is incredibly niche. With so many specialties and subsets, what you know and how it can help people is of the utmost importance. But the particular responsibilities the biotech field carries don’t necessarily mean employees are treated differently than they would be in some other industry. You can still put the same […]

presented by
News

How Biotech Is Revolutionizing Personalized Medicine

In 2005, my late father gave a lecture at Stanford University discussing personalized nutrition for cancer patients. He talked about nutrients that could be absorbed by both normal cells and cancer cells and would be customized to each patient’s unique status. Since then, personalized medicine has rapidly advanced and is becoming an increasingly larger market […]

MedCity Influencers

Regeneration Ability Isn’t Just for Superheroes

If you ever playacted superheroes as a kid, then you know that whoever claimed “healing” as his special power always enjoyed the most success. Thanks to huge strides in biotechnology, regenerative medicine is no longer just a playground pipe dream; it’s lauded as the next evolution of medical treatments. While most scientists are now in […]

MedCity Influencers

3 Biotech Trends That Will Change the World

I don’t know about you, but sometimes I think the latest biotechnology developments were ripped from the pages of a science fiction novel. Gene editing cures a little girl’s leukemia; an Italian doctor plans to perform the first human head transplant in 2017; and the U.S. Food and Drug Administration recently approved the first commercial […]